Top news from AHA: ISCHEMIA, dapagliflozin for HF, gout drug post-MI
Click Here to Manage Email Alerts
Healio and Cardiology Today reported live from the American Heart Association Scientific Sessions in Philadelphia, bringing readers the latest research and breaking news in cardiology.
We bring you the most-popular articles from the meeting, in no specific order. Find more coverage from the AHA Scientific Sessions here.
ISCHEMIA: Invasive strategy, medical therapy yield similar CV outcomes in stable ischemia
In stable patients with moderate or severe ischemia, an invasive strategy and a conservative strategy of optimal medical therapy yielded similar long-term CV outcomes, according to long-anticipated results of the ISCHEMIA and ISCHEMIA-CKD trials. Read more
Dapagliflozin confers consistent benefit in HF without diabetes: DAPA-HF
New analyses of the DAPA-HF trial suggest that the benefits of the SGLT2 inhibitor dapagliflozin extend beyond its effects as a type 2 diabetes therapy. Read more
COLCOT: Low-dose colchicine reduces CV risk after MI
In the COLCOT trial, adults with a recent MI were less likely to experience an ischemic CV event over 2 years when assigned the anti-inflammatory gout medication colchicine compared with assignment to placebo. Read more
ED visits spike, prescribing patterns change in wake of valsartan recall
When multiple generic valsartan products were recalled worldwide in July 2018 due to the presence of a carcinogenic contaminant, valsartan dispensing immediately decreased. However, there was an immediate spike in ED visits for hypertension and incomplete replacement with alternative products in some patients. Read more
Evening eating may worsen heart health in women
Women who consumed a higher proportion of their daily calories after 6 p.m. had poorer overall CV health and higher BP, BMI and HbA1c levels. Read more
Icosapent ethyl shows benefit on several plaque characteristics at 9 months: EVAPORATE
Interim data using coronary CT angiography demonstrated benefits of icosapent ethyl as an adjunct to statin therapy on several plaque characteristics at 9 months in adults with high triglycerides and coronary atherosclerosis. Read more
Twice-yearly inclisiran cuts LDL in ASCVD patients
New data on inclisiran, an investigational cholesterol-lowering therapy in the small-interfering RNA class, demonstrate sustained LDL reductions with twice-yearly dosing in high-risk patients with atherosclerotic CVD. Read more
Vitamin D, fish oil fail to reduce first HF hospitalization risk
Interventions with vitamin D or omega-3 failed to reduce rates of first heart failure hospitalization in a large cohort of healthy adults, although researchers observed a benefit for recurrent HF hospitalization with fish oil supplementation, according to findings from an ancillary study of the VITAL trial presented at the American Heart Association Scientific Sessions. Read more
GALILEO: Rivaroxaban raises death, thrombotic, bleeding risk vs. antiplatelet therapy after TAVR
Among patients who underwent successful transcatheter aortic valve replacement and were not on chronic oral anticoagulation, rivaroxaban was linked to higher risk for death/thromboembolic complications and bleeding compared with antiplatelet therapy. Read more
PARAGON-HF: Sacubitril/valsartan benefit in HFpEF most prominent in women, lower EF
Sacubitril/valsartan reduced the risk for HF hospitalization more in women compared with men, and the overall benefit of sacubitril/valsartan was driven by a benefit in patients with chronic HF and a left ventricular ejection fraction below the normal range, according to two analyses of the PARAGON-HF trial of patients with HF with preserved EF. Read more
Genetic testing may identify patients at risk for sudden cardiac death
Gene sequencing was used to identify a subset of the population predisposed to sudden cardiac death by a DNA variant. Read more
E-cigarette use negatively affects lipids, myocardial blood flow
Electronic cigarette use appears to have detrimental effects on lipid levels and myocardial blood flow compared with nonuse, according to results of two studies. Read more